Pharmaceutical and medical device companies operating in the U.S. must comply with strict Good Manufacturing Practices (GMPs) to ensure public safety, efficacy, and product quality. Yet, despite rigorous internal controls, …
Sia/LBG’s Andrew B. Harmon, a recognized subject matter expert providing strategic insights across the biopharmaceutical industry, recently presented a forward-looking model for the viral vector market at BioProcess International Europe …
We are proud to share that Patrick Falvey, Principal Consultant at Latham BioPharma Group (LBG), was featured in the American Pharmaceutical Review! In his interview, published on October 1, 2024, …
Cytokines have long been recognized for their potential in cancer immunotherapy, but achieving clinical success has remained a challenge. The recently published research article, “SON-1010: an albumin-binding IL-12 fusion protein …
We are excited to announce that LBG’s Robert Huebner will be speaking at the upcoming World Vaccine Congress Europe 2024! Robert will be presenting on the topic, “New Technologies for …
LBG’s Andrew Harmon is speaking at the BioProcess Insider’s State of the Industry Discussion. This discussion is being presented at BPI East 2024 in Boston. This engaging session will cover …
Georgia Sloboda, LBG’s Managing Director of Chemistry Manufacturing & Controls, will be presenting at the Bioprocessing Venture, Innovation & Partnering Conference on August 21st in Boston. Her topic, the Challenges …
“Sustainable manufacturing aims to improve on current manufacturing processes and create a far more ecologically friendly system without sacrificing productivity,” states Latham BioPharm Group, part of Sia Partners Patrick Falvey. …
Georgia Sloboda, Managing Director, CMC at LBG was recently recognized by The Corporate Magazine for her leadership expertise.
Written by LBG’s Dan Vest, “Avoiding Conflicts of Interest,” was recently published in Contract Management magazine. The article focuses on new legislation regarding Organizational Conflicts of Interest (OCIs), which was …